Therapeutic effect of MG132 on the aortic oxidative damage and inflammatory response in OVE26 type 1 diabetic mice

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2013, Pages

  Miao, Xiao ^a,b   Cui, Wenpeng ^a,b   Sun, Weixia ^b,c   Xin, Ying ^b,d   Wang, Bo ^b,e   Tan, Yi ^b,f   Cai, Lu ^b,f   Miao, Lining ^a   Fu, Yaowen ^c   Su, Guanfang ^a   Wang, Yuehui ^a  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

^c THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^d Basic Medical College   (China)

^e Inner Mongolia Forestry General Hospital   (China)

^f WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGE-MATCHED CONTROLS; CHRONIC TREATMENT; EFFECTIVE THERAPY; INFLAMMATORY RESPONSE; INTRAPERITONEALLY; OXIDATIVE DAMAGE; PATHOLOGICAL CHANGES; THERAPEUTIC EFFECTS;

MAMMALS; TRANSCRIPTION;

BLOOD VESSELS;

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; 3 NITROTYROSINE; 3-NITROTYROSINE; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; DRUG DERIVATIVE; LEUPEPTIN; TRANSFORMING GROWTH FACTOR BETA1; TYROSINE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA DISEASE; ARTERIAL WALL THICKNESS; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC TRANSCRIPTION; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MOUSE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TREATMENT DURATION; ANIMAL; AORTA; BLOOD PRESSURE; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENETICS; METABOLISM; PATHOLOGY; UPREGULATION;

MUS;

ALBUMINURIA; ANIMALS; AORTA; BLOOD PRESSURE; DIABETES MELLITUS, EXPERIMENTAL; HYPERGLYCEMIA; LEUPEPTINS; MICE; MICE, TRANSGENIC; NF-E2-RELATED FACTOR 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE; UP-REGULATION;

EID: 84876592408     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2013/879516     Document Type: Article

References (32)

1. King G. L., Loeken M. R., Hyperglycemia-induced oxidative stress in diabetic complications. Histochemistry and Cell Biology 2004 122 4 333 338 2-s2.0-8644267972 10.1007/s00418-004-0678-9 (Pubitemid 39506591)
2. Jeong I. K., King G. L., New perspectives on diabetic vascular complications: the loss of endogenous protective factors induced by hyperglycemia. Diabetes & Metabolism Journal 2011 35 1 8 11
3. Lee J. M., Johnson J. A., An important role of Nrf2-ARE pathway in the cellular defense mechanism. Journal of Biochemistry and Molecular Biology 2004 37 2 139 143 2-s2.0-2342514015 (Pubitemid 38608865)
4. Tkachev V. O., Menshchikova E. B., Zenkov N. K., Mechanism of the Nrf2/Keap1/ARE signaling system. Biochemistry 2011 76 4 407 422 2-s2.0-79958255513 10.1134/S0006297911040031
5. Li B., Liu S., Miao L., Cai L., Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy. Experimental Diabetes Research 2012 2012 7 216512 10.1155/2012/216512
6. Jalonen U., Paukkeri E. L., Moilanen E., Compounds that increase or mimic cyclic adenosine monophosphate enhance tristetraprolin degradation in lipopolysaccharide-treated murine J774 macrophages. Journal of Pharmacology and Experimental Therapeutics 2008 326 2 514 522 2-s2.0-47949116256 10.1124/jpet.107.133702
7. He X., Kan H., Cai L., Ma Q., Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. Journal of Molecular and Cellular Cardiology 2009 46 1 47 58 2-s2.0-57249104720 10.1016/j.yjmcc.2008.10. 007
8. Jiang T., Huang Z., Lin Y., Zhang Z., Fang D., Zhang D. D., The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 2010 59 4 850 860 2-s2.0-77951199503 10.2337/db09-1342
9. de Haan J. B., Nrf2 activators as attractive therapeutics for diabetic nephropathy. Diabetes 2011 60 11 2683 2684
10. Ungvari Z., Bailey-Downs L., Gautam T., Jimenez R., Losonczy G., Zhang C., Ballabh P., Recchia F. A., Wilkerson D. C., Sonntag W. E., Pearson K., de Cabo R., Csiszar A., Adaptive induction of NF-E2-related factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia. American Journal of Physiology 2011 300 4 H1133 H1140 2-s2.0-79955068967 10.1152/ajpheart.00402.2010
11. Ungvari Z., Bailey-Downs L., Sosnowska D., Gautam T., Koncz P., Losonczy G., Ballabh P., de Cabo R., Sonntag W. E., Csiszar A., Vascular oxidative stress in aging: a homeostatic failure due to dysregulation of NRF2-mediated antioxidant response. American Journal of Physiology 2011 301 2 H363 H372 2-s2.0-79961043903 10.1152/ajpheart.01134.2010
12. Liu H., Yu S., Xu W., Xu J., Enhancement of 26S proteasome functionality connects oxidative stress and vascular endothelial inflammatory response in diabetes mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 9 2131 2140
13. Wilck N., Fechner M., Dreger H., Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 6 1418 1426
14. Epstein P. N., Overbeek P. A., Means A. R., Calmodulin-induced early-onset diabetes in transgenic mice. Cell 1989 58 6 1067 1073 2-s2.0-0024459130 (Pubitemid 19238184)
15. Zheng S., Noonan W. T., Metreveli N. S., Coventry S., Kralik P. M., Carlson E. C., Epstein P. N., Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 2004 53 12 3248 3257 2-s2.0-9444262472 10.2337/diabetes.53.12.3248 (Pubitemid 39564502)
16. Luo Z. F., Qi W., Feng B., Mu J., Zeng W., Guo Y. H., Pang Q., Ye Z. L., Liu L., Yuan F. H., Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome. Life Sciences 2011 88 11-12 512 520 2-s2.0-79952455513 10.1016/j.lfs.2010.12.023
17. Chen B., Ma Y., Meng R., Xiong Z., Zhang C., Chen G., Zhang A., Dong Y., MG132, a proteasome inhibitor, attenuates pressure-overload-induced cardiac hypertrophy in rats by modulation of mitogen-activated protein kinase signals. Acta Biochimica et Biophysica Sinica 2010 42 4 253 258 2-s2.0-77950553729 10.1093/abbs/gmq012
18. Meiners S., Hocher B., Weller A., Laule M., Stangl V., Guenther C., Godes M., Mrozikiewicz A., Baumann G., Stangl K., Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension 2004 44 4 471 477 2-s2.0-4644306893 10.1161/01.HYP.0000142772.71367.65 (Pubitemid 39281498)
19. Feng M., Deerhake M. E., Keating R., Thaisz J., Xu L., Tsaih S. W., Smith R., Ishige T., Sugiyama F., Churchill G. A., DiPetrillo K., Genetic analysis of blood pressure in 8 mouse intercross populations. Hypertension 2009 54 4 802 809 2-s2.0-70349656061 10.1161/HYPERTENSIONAHA.109.134569
20. Bai S. Z., Sun J., Wu H., Decrease in calcium-sensing receptor in the progress of diabetic cardiomyopathy. Diabetes Research and Clinical Practice 2012 95 3 378 385
21. Bai Y., Tan Y., Wang B., Deletion of angiotensin II type 1 receptor gene or scavenge of superoxide prevents chronic alcohol-induced aortic damage and remodelling. Journal of Cellular and Molecular Medicine 2012 16 10 2530 2538
22. Pergola P. E., Krauth M., Huff J. W., Ferguson D. A., Ruiz S., Meyer C. J., Warnock D. G., Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD. American Journal of Nephrology 2011 33 5 469 476 2-s2.0-79954582442 10.1159/000327599
23. Pergola P. E., Raskin P., Toto R. D., Meyer C. J., Huff J. W., Grossman E. B., Krauth M., Ruiz S., Audhya P., Christ-Schmidt H., Wittes J., Warnock D. G., Bardoxolone methyl and kidney function in CKD with type 2 diabetes. The New England Journal of Medicine 2011 365 4 327 336 2-s2.0-79960855656 10.1056/NEJMoa1105351
24. Inada A., Kanamori H., Arai H., Akashi T., Araki M., Weir G. C., Fukatsu A., A model for diabetic nephropathy: advantages of the inducible cAMP early repressor transgenic mouse over the streptozotocin-induced diabetic mouse. Journal of Cellular Physiology 2008 215 2 383 391 2-s2.0-40949101317 10.1002/jcp.21316 (Pubitemid 351468950)
25. Wold L. E., Ren J., Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinase-dependent oxidative stress mechanism. Biochemical and Biophysical Research Communications 2004 318 4 1066 1071 2-s2.0-2442550992 10.1016/j.bbrc.2004.04.138 (Pubitemid 38625884)
26. Teiken J. M., Audettey J. L., Laturnus D. I., Zheng S., Epstein P. N., Carlson E. C., Podocyte loss in aging OVE26 diabetic mice. Anatomical Record 2008 291 1 114 121 2-s2.0-40949086493 10.1002/ar.20625
27. Yang J., Tan Y., Zhao F., Ma Z., Wang Y., Zheng S., Epstein P. N., Yu J., Yin X., Zheng Y., Li X., Miao L., Cai L., Angiotensin II plays a critical role in diabetic pulmonary fibrosis most likely via activation of nadph oxidase-mediated nitrosative damage. American Journal of Physiology 2011 301 1 E132 E144 2-s2.0-79959575387 10.1152/ajpendo.00629.2010
28. Oelze M., Knorr M., Schuhmacher S., Heeren T., Otto C., Schulz E., Reifenberg K., Wenzel P., Münzel T., Daiber A., Vascular dysfunction in streptozotocin-induced experimental diabetes strictly depends on insulin deficiency. Journal of Vascular Research 2011 48 4 275 284 2-s2.0-79151484305 10.1159/000320627
29. Gao X., Zhang H., Schmidt A. M., Zhang C., AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. American Journal of Physiology 2008 295 2 H491 H498 2-s2.0-52449094718 10.1152/ajpheart.00464.2008
30. Singh A. B., Guleria R. S., Nizamutdinova I. T., Baker K. M., Pan J., High glucose-induced repression of RAR/RXR in cardiomyocytes is mediated through oxidative stress/JNK signaling. Journal of Cellular Physiology 2012 227 6 2632 2644
31. Wang S., Zhang M., Liang B., Xu J., Xie Z., Liu C., Viollet B., Yan D., Zou M. H., AMPK α 2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circulation Research 2010 106 6 1117 1128 2-s2.0-77950989801 10.1161/CIRCRESAHA.109.212530
32. Xu J., Wang S., Zhang M., Wang Q., Asfa S., Zou M. H., Tyrosine nitration of PA700 links proteasome activation to endothelial dysfunction in mouse models with cardiovascular risk factors. PLoS ONE 2012 7 1 e29649